Cowen Comments On MEI Pharma Following Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia
Cowen analyst Boris Peaker reiterated an Outperform rating on MEI Pharma (NASDAQ:MEIP), as the company reported clinical activity from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (AML). No price target was provided.
Peaker commented: “We had an opportunity to discuss the data with the trial investigator. While he was cautious about drawing an analogy between the AML and the ongoing MDS trials, he had a positive outlook on the MDS study.” The analyst added, “We believe that the results from the randomized, blinded, Phase II study of pracinostat is the next key milestone for MEIP, and is the most significant event in the company’s history.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Boris Peaker has a total average return of 29.7% and a 66.7% success rate. Peaker is ranked #90 out of 3401 analysts.